Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study

Back

ESC Premium Access

Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study

Session: Oral Anticoagulant Therapy in the Elderly with Atrial Fibrillation

Topic: Oral Anticoagulation

Speaker: Doctor O. Rutherford (Sarpsborg, NO)

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Doctor Ole-Christian Walter Rutherford

Sykehuset Ostfold Kalnes, Sarpsborg (Norway)

0 follower

5 more presentations in this session

Real-world effectiveness and the safety of anticoagulant treatment in elderly non-valvular atrial fibrillation in the ANAFIE registry, the largest real-world elderly AF registry

Speaker: Doctor T. Yamashita (Tokyo, JP)

Edoxaban treatment of elderly patients with atrial fibrillation in routine clinical practice: 1-year results of the non-interventional Global ETNA-AF program

Speaker: Doctor T. Yamashita (Tokyo, JP)

Oral anticoagulants in extremely high risk very elderly (>90 years) patients with Atrial Fibrillation

Speaker: Doctor T. Chao (Taipei, TW)

Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF Registry sub-cohort analysis

Speaker: Doctor S. Suzuki (Tokyo, JP)

Bleeding risks with frailty and multimorbidity in patients with atrial fibrillation. A nationwide analysis of 1.4 million subjects

Speaker: Professor L. Fauchier (Tours, FR)

Access the full session

Oral Anticoagulant Therapy in the Elderly with Atrial Fibrillation

Speakers: Doctor O. Rutherford, Doctor T. Yamashita, Doctor T. Yamashita, Doctor T. Chao, Doctor S. Suzuki...

Access

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources